Protein’s Second Role in Inflammation Could Reshape Treatment for Crohn’s, Arthritis and Heart Disease

In a breakthrough that could redefine therapeutic strategies for chronic inflammatory diseases, researchers have uncovered a novel function of the protein inducible nitric oxide synthase (iNOS), long recognized solely for its role in producing nitric oxide (NO) during inflammatory responses. This newly identified role reveals that iNOS physically interacts with the mitochondrial protein IRG1, directly regulating immune cell metabolism and inflammation independent of NO production. Published in the prestigious journal Nature Metabolism, this discovery opens the door to innovative drug targets aimed at precisely modulating the immune response in diseases such as cardiovascular disorders, arthritis, and Crohn’s disease.

The immune system responds to infection or injury by activating inflammation, a complex biological process geared towards eliminating threats and initiating tissue repair. While essential for survival, unrestrained or chronic inflammation underpins the pathogenesis of numerous debilitating diseases. Unraveling the molecular mechanisms controlling the intensity and duration of inflammation represents a critical challenge in modern medicine. The newly reported interaction between iNOS and IRG1 adds a significant piece to this puzzle, presenting a specialized molecular checkpoint that could be harnessed therapeutically.

Until now, the immunological role of iNOS was predominantly attributed to its enzymatic generation of nitric oxide, a reactive molecule involved in killing pathogens and signaling to immune cells. However, researchers from the University of Surrey and the University of Oxford have demonstrated that iNOS’s regulatory effects extend beyond its catalytic activity.

Understanding the iNOS-IRG1 Interaction

The study reveals that iNOS binds directly to IRG1, a protein involved in the metabolism of itaconate, an anti-inflammatory compound produced in macrophages. This interaction modulates the metabolic state of immune cells, influencing their inflammatory potential without altering nitric oxide synthesis. By targeting this protein-protein interface, it may be possible to develop drugs that fine-tune inflammatory responses in specific tissues, reducing side effects associated with broad immunosuppression.

This mechanism offers a promising avenue for treating conditions where inflammation plays a central role, including atherosclerosis—a key driver of cardiovascular disease—rheumatoid arthritis, and inflammatory bowel diseases such as Crohn’s disease. Current therapies often face limitations due to incomplete efficacy or adverse effects stemming from global immune inhibition. The iNOS-IRG1 pathway presents an opportunity for more precise intervention.

Implications for Cardiovascular Disease, Arthritis and Crohn’s Disease

In cardiovascular disease, persistent inflammation contributes to plaque formation and instability in arteries, increasing the risk of heart attack and stroke. The ability to modulate immune cell metabolism via the iNOS-IRG1 axis could help attenuate vascular inflammation without compromising host defense.

Similarly, in rheumatoid arthritis, synovial joint inflammation leads to cartilage and bone damage. Targeting metabolic checkpoints in inflammatory cells may offer a way to reduce joint destruction while preserving systemic immunity.

For Crohn’s disease, characterized by chronic inflammation of the gastrointestinal tract, dysregulation of immune responses in the gut mucosa drives symptoms such as abdominal pain, diarrhea, and weight loss. Modulating the iNOS-IRG1 interaction could help restore homeostasis in intestinal immune cells, potentially leading to longer remission periods.

Future Directions and Therapeutic Potential

While the findings are promising, further research is needed to validate the therapeutic potential of targeting the iNOS-IRG1 interaction in preclinical models and eventually in human clinical trials. Scientists will need to develop small molecules or biologics that can disrupt or enhance this specific interaction depending on the disease context.

The discovery also underscores the importance of exploring non-canonical functions of well-studied proteins. As our understanding of immunometabolism deepens, such moonlighting activities may reveal new layers of regulatory control in health and disease.

By shifting focus from nitric oxide production to protein-mediated metabolic regulation, this work expands the toolkit available for developing next-generation anti-inflammatory therapies. For patients living with chronic inflammatory conditions, it offers hope for more effective and safer treatment options in the years ahead.